poisar

Stocks · News reference

BTIG Reiterates Buy on Medline, Maintains $55 Price Target

BenzingaAug 27, 2026, 11:44 AMBenzinga Newsdesk

BTIG analyst David Larsen reiterates Medline (NASDAQ:MDLN) with a Buy and maintains $55 price target.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Aug 27, 2026, 11:44 AM
Checked
Aug 27, 2026, 11:44 AM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading